SPEAKER
Felipe de Sousa e Melo
Abstract
Exploiting the oncogenic state of colorectal cancer for therapeutic development.
Affiliation
Group leader, Genentech, United States.
Research interests
Dr. Felipe de Sousa e Melo leads a discovery research group operating at the interface between technology and biology with a specific emphasis on colorectal cancer biology. More specifically, his team has generated bispecific antibodies that can tether these E3 ubiquitin ligases to a variety of cell surface receptors to promote tumor receptor degradation. This platform has been dubbed PROTABs for Proteolysis Targeting Antibodies.
Zoom meeting link
http://us06web.zoom.us/j/87875918204?pwd=V0x3bmxseFAxZ00rSGhoYUVPSXIKZz09
Meeting ID
878 7591 8204
Passcode
2023CGE
